Visual Abstract: Sacubitril/Valsartan vs Standard Medical Therapy on Plasma NT-proBNP, Exercise Capacity in Patients With Heart Failure

JAMA

EMBARGOED FOR RELEASE: 11 A.M. (ET), TUESDAY, NOVEMBER 16, 2021

Media advisory: The full study and editorial are linked to this news release. A visual abstract is below.

Embed this link to provide your readers free access to the full-text article This link will be live at the embargo time https://jamanetwork.com/journals/jama/fullarticle/10.1001/jama.2021.18463?guestAccessKey=3343fbdc-dcc0-4a1e-acb4-2a91b8a7f5c3&utm_source=For_The_Media&utm_medium=referral&utm_campaign=ftm_links&utm_content=tfl&utm_term=111621

 

Visual Abstract

 

Authors: Burkert Pieske, M.D., of Charité University Medicine in Berlin, is the corresponding author.

(doi:10.1001/jama.2021.18463)

Editor’s Note: Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support.

#  #  #

For more information, contact JAMA Network Media Relations at 312-464-JAMA (5262) or email media relations.